{"disease":{"id":"lymphoma-large-b-cell-diffuse","name":"lymphoma large b cell diffuse"},"drugs":{"marketed":[{"drug_id":"tafasitamab","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xmab5574","generic_name":"tafasitamab","company_name":"Morphosys Us Inc","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":null,"revenue":"100","mechanism":"Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells."},{"drug_id":"tafasitamab-cxix","indication_name":"Malignant lymphoma, large B-cell, diffuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MONJUVI","generic_name":"TAFASITAMAB-CXIX","company_name":"MORPHOSYS US INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05169203","title":"The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":2969,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT03646422","title":"AEDV Registry of Primary Cutaneous Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Fundación Academia Española de Dermatología","has_results":false},{"nct_id":"NCT06890884","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01649856","title":"A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02285062","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT01787409","title":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05421663","title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":439,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06573645","title":"A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":428,"lead_sponsor_name":"Xia Yi","has_results":false},{"nct_id":"NCT04799275","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":422,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05633615","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01856192","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":349,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05318391","title":"Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05466318","title":"ChiCGB vs BEAM in High-risk or R/R Lymphomas","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT01421524","title":"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT07309497","title":"Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT07519772","title":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03977623","title":"Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07305337","title":"Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","phase":"NA","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT01307267","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02031419","title":"Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":174,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04317313","title":"18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":true},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05130489","title":"CAR T Cell Therapy Related Cardiovascular Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University College London Hospitals","has_results":false},{"nct_id":"NCT04799314","title":"PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT02916316","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","phase":"","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT05798156","title":"Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT06238648","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT03293173","title":"Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Nordic Lymphoma Group","has_results":false},{"nct_id":"NCT06649812","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04446962","title":"LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT00901615","title":"Lenalidomide and R-CHOP in B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Lymphoma Study Association","has_results":false},{"nct_id":"NCT01193842","title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03744676","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT03211702","title":"Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Chonbuk National University Hospital","has_results":false},{"nct_id":"NCT07270263","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04789434","title":"PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":94,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04849416","title":"A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06015464","title":"An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL","phase":"","overall_status":"UNKNOWN","enrollment_count":81,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04271410","title":"CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03418038","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05728632","title":"Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Giulio Stefanini","has_results":false},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02417285","title":"A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03483103","title":"Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}